Track topics on Twitter Track topics that are important to you
Pharmaceutical rivals will to try to exploit Teva's weakness and buy activities from it that are profitable, writes Omri Cohen.
Original Article: Nobody would buy Teva because of its debtNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...